Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta

doi:10.1038/nrd.2015.9

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

Chiara Degirolamo, Carlo Sabbà, Antonio Moschetta

Pharmacology

Research output: Contribution to journal › Review article › peer-review

322 Scopus citations

Abstract

The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.

Original language	English (US)
Pages (from-to)	51-69
Number of pages	19
Journal	Nature Reviews Drug Discovery
Volume	15
Issue number	1
DOIs	https://doi.org/10.1038/nrd.2015.9
State	Published - Jan 1 2016

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1038/nrd.2015.9

Cite this

@article{645a42bd146047fa9aeab150decf0fa7,

title = "Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23",

abstract = "The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.",

author = "Chiara Degirolamo and Carlo Sabb{\`a} and Antonio Moschetta",

year = "2016",

month = jan,

day = "1",

doi = "10.1038/nrd.2015.9",

language = "English (US)",

volume = "15",

pages = "51--69",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

AU - Degirolamo, Chiara

AU - Sabbà, Carlo

AU - Moschetta, Antonio

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.

AB - The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.

UR - http://www.scopus.com/inward/record.url?scp=84955209323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955209323&partnerID=8YFLogxK

U2 - 10.1038/nrd.2015.9

DO - 10.1038/nrd.2015.9

M3 - Review article

C2 - 26567701

AN - SCOPUS:84955209323

SN - 1474-1776

VL - 15

SP - 51

EP - 69

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 1

ER -

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this